BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD3470 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD3470\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06130553-11150@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20281204
DTEND;VALUE=DATE:20281205
SUMMARY:AZD3470: Phase 1/2 readout est. (NCT06130553)
DESCRIPTION:AZD3470\, phase 1/2.\nStudy: A Study of AZD3470\, a PRMT5 Inhib
 itor\, Given as Monotherapy and in Combination in Patients With MTAP Defic
 ient Advanced/Metastatic Solid Tumors\nEstimated primary completion: 4 Dec
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azd3470#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06130
 553
URL:https://assetmemo.bio/drug/azd3470#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06137144-11150@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20290503
DTEND;VALUE=DATE:20290504
SUMMARY:AZD3470: Phase 1/2 readout est. (NCT06137144)
DESCRIPTION:AZD3470\, phase 1/2.\nStudy: AZD3470 as Monotherapy or in Combi
 nation With Anticancer Agent(s) in Participants With Haematologic Malignan
 cies.\nEstimated primary completion: 3 May 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/azd3470#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06137144
URL:https://assetmemo.bio/drug/azd3470#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
